文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

碳青霉烯类与非碳青霉烯类广谱β-内酰胺类抗生素作为脓毒症初始治疗的疗效比较:一项全国性观察性研究

Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study.
PubMed 文献 · Crit Care Med · 2023-05-26
一句话结论脓毒症初始治疗中,碳青霉烯类与非碳青霉烯类广谱β-内酰胺类相比未显著降低住院死亡率(校正OR 0.88,p=0.108)。

该多中心回顾性观察研究利用日本大型数据库,纳入2006年至2019年诊断为脓毒症的成人患者7392例,其中3547例接受碳青霉烯类初始治疗,3845例接受非碳青霉烯类广谱β-内酰胺类初始治疗。采用倾向评分逆概率治疗加权校正的逻辑回归模型比较两组住院死亡率,结果显示碳青霉烯类治疗与较低死亡率无显著关联(校正OR 0.88,p=0.108)。亚组分析提示,在脓毒症休克、ICU内或接受机械通气的患者中,碳青霉烯类治疗可能带来显著生存获益(效应修饰p值分别为<0.001、0.014和0.105)。

要点

  • 在7392例脓毒症成人患者中,碳青霉烯类初始治疗与非碳青霉烯类广谱β-内酰胺类相比,住院死亡率无显著差异(校正OR 0.88,p=0.108)。
  • 亚组分析提示脓毒症休克患者中碳青霉烯类治疗可能显著改善生存(效应修饰p<0.001)。
  • ICU内脓毒症患者中碳青霉烯类治疗可能显著改善生存(效应修饰p=0.014)。
  • 接受机械通气的脓毒症患者中碳青霉烯类治疗的生存获益效应修饰p=0.105。
  • 研究设计为多中心回顾性观察性研究,结果需结合患者特征个体化解读。

适用人群与场景

  • 2006年至2019年日本三级医院诊断为脓毒症的成人患者。

处置流程与药物剂量

  • 初始抗生素治疗为碳青霉烯类或非碳青霉烯类广谱β-内酰胺类(如哌拉西林-他唑巴坦和第四代头孢菌素)。

研究设计与关键结果

  • 研究类型:多中心回顾性观察性研究;样本量:7392例脓毒症成人患者;干预与对照:碳青霉烯类初始治疗(3547例) vs 非碳青霉烯类广谱β-内酰胺类初始治疗(3845例)。
  • 主要终点:住院死亡率,采用倾向评分逆概率治疗加权校正的逻辑回归模型,碳青霉烯类治疗与较低死亡率无显著关联(校正OR 0.88,p=0.108)。
  • 亚组分析:脓毒症休克患者中碳青霉烯类治疗有显著生存获益(效应修饰p<0.001);ICU患者中有显著生存获益(效应修饰p=0.014);机械通气患者中效应修饰p=0.105。

证据类型、等级与局限

  • 证据类型:多中心回顾性观察性研究;局限:原文未报告局限性。

对床旁实践的改变

  • 对于脓毒症初始治疗,碳青霉烯类与非碳青霉烯类广谱β-内酰胺类相比未显著降低住院死亡率(校正OR 0.88,p=0.108)。
  • 在脓毒症休克、ICU内或接受机械通气的患者中,碳青霉烯类初始治疗可能带来生存获益(效应修饰p值分别为<0.001、0.014和0.105)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: As causative pathogens are not usually identified at the time of initiating antibiotics in sepsis, carbapenems are commonly used as an initial treatment. To reduce indiscriminate use of carbapenems, the efficacy of alternative empiric regimens, such as piperacillin-tazobactam and the fourth-generation cephalosporins, should be elucidated. This study aimed to evaluate survival effect associated with carbapenems as initial therapy for sepsis compared with these antibiotics.

DESIGN: Multicenter retrospective observational study.

SETTING: Tertiary hospitals in Japan.

PATIENTS: Adult patients diagnosed as having sepsis from 2006 to 2019.

INTERVENTIONS: Administration of carbapenems as initial antibiotic therapy.

MEASUREMENTS AND MAIN RESULTS: This study used data of adult patients with sepsis extracted from a large-scale database in Japan. Patients were divided into two groups as follows: patients receiving carbapenems and patients receiving noncarbapenem broad-spectrum beta-lactam antibiotics as initial treatment. In-hospital mortality was compared between the groups by a logistic regression model adjusted by an inverse probability treatment weighting using propensity scores. To evaluate heterogeneity of effects according to patient characteristics, we also fitted logistic models in several subgroups. Among 7,392 patients with sepsis, 3,547 patients received carbapenems, and 3,845 patients received noncarbapenem agents. The logistic model showed no significant association between carbapenem therapy and lower mortality (adjusted OR 0.88, p = 0.108). Subgroup analyses suggested that there were significant survival benefits associated with carbapenem therapy in patients with septic shock, in ICUs, or with mechanical ventilation ( p for effect modifications: < 0.001, 0.014, and 0.105, respectively).

CONCLUSIONS: Compared with the noncarbapenem broad-spectrum antibiotics, carbapenems as an initial therapy for sepsis were not associated with significantly lower mortality.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Umemura Y, Yamakawa K, Tanaka Y, et al. Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study. Crit Care Med. 2023. PMID: 37232855. doi:10.1097/CCM.0000000000005932

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。